Mark Corbett, Senior Vice President of Clinigen Global Access Programs answered a few questions on the UK’s Early Access to Medicines Scheme (EAMS). In this discussion Mark outlined his recommendations for the UK to move forward, enabling earlier access to drugs for those with rare diseases.
In his answers, Mark covers:
- Whether or not EAMS is a positive step forward
- How the UK currently rates in comparison with other global access programmes
- Top 5 recommendations for moving forward, to enable earlier access to drugs for those with rare diseases
…and much more!
If you are interested in hearing more from Mark, he will be joining us as a guest speaker at the inaugural Fast Tracking Orphan Drugs Briefing on 10th July 2014 in London. Download the agenda here.